Correlation Between International Biotechnology and Sabre Insurance

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both International Biotechnology and Sabre Insurance at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining International Biotechnology and Sabre Insurance into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between International Biotechnology Trust and Sabre Insurance Group, you can compare the effects of market volatilities on International Biotechnology and Sabre Insurance and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in International Biotechnology with a short position of Sabre Insurance. Check out your portfolio center. Please also check ongoing floating volatility patterns of International Biotechnology and Sabre Insurance.

Diversification Opportunities for International Biotechnology and Sabre Insurance

-0.4
  Correlation Coefficient

Very good diversification

The 3 months correlation between International and Sabre is -0.4. Overlapping area represents the amount of risk that can be diversified away by holding International Biotechnology Tr and Sabre Insurance Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sabre Insurance Group and International Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on International Biotechnology Trust are associated (or correlated) with Sabre Insurance. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sabre Insurance Group has no effect on the direction of International Biotechnology i.e., International Biotechnology and Sabre Insurance go up and down completely randomly.

Pair Corralation between International Biotechnology and Sabre Insurance

Assuming the 90 days trading horizon International Biotechnology Trust is expected to generate 1.07 times more return on investment than Sabre Insurance. However, International Biotechnology is 1.07 times more volatile than Sabre Insurance Group. It trades about 0.07 of its potential returns per unit of risk. Sabre Insurance Group is currently generating about -0.11 per unit of risk. If you would invest  68,600  in International Biotechnology Trust on August 31, 2024 and sell it today you would earn a total of  1,400  from holding International Biotechnology Trust or generate 2.04% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

International Biotechnology Tr  vs.  Sabre Insurance Group

 Performance 
       Timeline  
International Biotechnology 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in International Biotechnology Trust are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound technical and fundamental indicators, International Biotechnology is not utilizing all of its potentials. The newest stock price tumult, may contribute to shorter-term losses for the shareholders.
Sabre Insurance Group 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Sabre Insurance Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

International Biotechnology and Sabre Insurance Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with International Biotechnology and Sabre Insurance

The main advantage of trading using opposite International Biotechnology and Sabre Insurance positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if International Biotechnology position performs unexpectedly, Sabre Insurance can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sabre Insurance will offset losses from the drop in Sabre Insurance's long position.
The idea behind International Biotechnology Trust and Sabre Insurance Group pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Other Complementary Tools

Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Bonds Directory
Find actively traded corporate debentures issued by US companies